Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E D Williamson

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Clinical and Experimental Immunology|April 12, 2019
Vaccines for emerging pathogens: prospects for licensureE D Williamson, G E Westlake
Journal of Medical Microbiology|March 24, 2012
The natural history and incidence of Yersinia pestis and prospects for vaccinationE D Williamson, P C F Oyston
Clinical and Experimental Immunology|March 14, 2013
Protecting against plague: towards a next-generation vaccineE D Williamson, P C F Oyston
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 24, 2007
Intranasal administration of influenza vaccines: current statusJ E Eyles, E D Williamson, H O Alpar
International Journal of Pharmaceutics|October 16, 1999
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volumeJ E Eyles, E D Williamson, H O Alpar
FEMS Microbiology Letters|June 1, 1993
Biochemical and immunological properties of the C-terminal domain of the alpha-toxin of Clostridium perfringensR W Titball, A M Fearn, E D Williamson
Vaccine|August 3, 2001
Passive transfer of protection against Bacillus anthracis infection in a murine modelR J Beedham, P C Turnbull, E D Williamson
Infection and Immunity|August 26, 1998
The pH 6 antigen of Yersinia pestis binds to beta1-linked galactosyl residues in glycosphingolipidsD Payne, D Tatham, E D Williamson, et al.
Vaccine|August 19, 2003
Protective efficacy of a fully recombinant plague vaccine in the guinea pigS M Jones, K F Griffin, I Hodgson, et al.
Microbiology (Reading, England)|July 1, 1996
An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in miceP C Oyston, P Russell, E D Williamson, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Clinical and Experimental Immunology|April 12, 2019
Vaccines for emerging pathogens: prospects for licensureE D Williamson, G E Westlake
Journal of Medical Microbiology|March 24, 2012
The natural history and incidence of Yersinia pestis and prospects for vaccinationE D Williamson, P C F Oyston
Clinical and Experimental Immunology|March 14, 2013
Protecting against plague: towards a next-generation vaccineE D Williamson, P C F Oyston
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 24, 2007
Intranasal administration of influenza vaccines: current statusJ E Eyles, E D Williamson, H O Alpar
International Journal of Pharmaceutics|October 16, 1999
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volumeJ E Eyles, E D Williamson, H O Alpar
FEMS Microbiology Letters|June 1, 1993
Biochemical and immunological properties of the C-terminal domain of the alpha-toxin of Clostridium perfringensR W Titball, A M Fearn, E D Williamson
Vaccine|August 3, 2001
Passive transfer of protection against Bacillus anthracis infection in a murine modelR J Beedham, P C Turnbull, E D Williamson
Infection and Immunity|August 26, 1998
The pH 6 antigen of Yersinia pestis binds to beta1-linked galactosyl residues in glycosphingolipidsD Payne, D Tatham, E D Williamson, et al.
Vaccine|August 19, 2003
Protective efficacy of a fully recombinant plague vaccine in the guinea pigS M Jones, K F Griffin, I Hodgson, et al.
Microbiology (Reading, England)|July 1, 1996
An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in miceP C Oyston, P Russell, E D Williamson, et al.
Pageof 8